Key Clinical Summary: Optimizing Outcomes in Advanced ALK-Positive NSCLC

This microlearning module summarizes the presentations by Dr. Urs Weber and Dr. Kyle Concannon, which you can view here. Before participating, please read our information on continuing medical education (CME) and disclosure, available here.

This program is supported by an independent educational grant from Pfizer. This educational program has been designed for healthcare professionals worldwide.

1. Patient-Centered Preparation at Treatment Initiation

Goal Setting and Expectations: Align targeted therapy initiation with individual patient priorities, such as preserving cognitive function, maintaining independent living, or continuing employment. Clarify treatment goals upfront (prolonging survival, tumor control, quality-of-life maintenance) so patients understand expected outcomes.
Baseline Risk and Toxicity Education: Outline expected adverse event (AE) profiles for targeted agents (e.g., third-generation ALK inhibitors like lorlatinib), including central nervous system (CNS)/neurocognitive effects, hyperlipidemia, hepatic transaminase elevations, and peripheral edema or neuropathy.
Structuring Dosing and Tolerability Strategies: Acknowledge that starting at lower dose levels (or utilizing dose reductions) can preserve efficacy while significantly lowering toxicity rates for susceptible patients.
Comprehensive Readiness Assessment: Evaluate patient readiness across five key domains before initiating therapy:
Knowledge/Understanding: Use the "teach-back" method to verify the patient can state key red-flag symptoms.
Practical Capacity: Assess ability to adhere to dosing schedules, store medications, and attend appointments.
Social Support: Identify primary care partners and clarify their supportive role.
Language & Health Literacy: Provide culturally appropriate, bilingual materials at reading levels suited to the patient.
Emotional Status: Screen for disease-related distress or anxiety and offer immediate supportive measures.

2. Proactive, Multidisciplinary Adverse-Event Recognition & Management

Timeline of Onset: Monitor closely during the initial days to weeks of treatment, as many targeted TKI adverse events manifest early in the treatment course.
Identifying Subtle Neurocognitive and Functional Changes:

Screen routinely for subtle early signs: forgetfulness, word-finding difficulty, reduced attention span, altered sleep patterns, irritability, apathy, or mood swings.
Track functional indicators such as task completion delays, work errors, or needing new reminders for daily activities.
Leverage care partner observations, as family members frequently notice subtle personality or behavioral shifts before the patient recognizes them.
Rapid Clinical Triage and Workup:
Perform rapid bedside or remote functional screens (orientation, counting backwards, item recall, medication management capability).
Acute Escalation Triggers: Immediate evaluation in an urgent or emergency setting is required for acute confusion, hallucinations, seizures, focal neurological deficits, or sudden loss of independence.
Rule out medical or oncologic emergencies (e.g., stroke, disease progression, hypoglycemia, acute drug-drug interactions) via laboratory testing, blood glucose checks, and brain MRI prior to attributing symptoms solely to drug toxicity.
Actionable AE Mitigation Protocols:
Mild Toxicity / Non-Functional Impact: Continue therapy with close monitoring or supportive strategies (e.g., lifestyle modifications, lipid-lowering agents).
Moderate-to-Severe Toxicity / Functional Impairment: Implement temporary treatment holds to allow recovery to baseline, followed by dose reductions. Reassess within one month of any modification to confirm symptom resolution.

3. Active Patient and Care Partner Participation in Symptom Monitoring

Low-Tech Communication Tools: For patients with limited digital access or transportation barriers, provide simple, low-tech solutions:

A bilingual one-page start-up checklist detailing dosing instructions, scheduled lab checks, and emergency contacts.
A symptom diary utilizing simple scales (e.g., 0–3) or prompts focused on memory, sleep, mood, and fall history.
Structured Caller Scripts: Educate care partners to report changes using clear, concrete communication frameworks (e.g., "T_oday [Patient] did [specific action], and now exhibits [specific symptom_]") to assist triage personnel.
Immediate Home Safety Protocols: Instruct caregivers on actionable home safety steps when neurological changes occur, including stopping driving immediately, securing hazardous appliances, utilizing pill organizers, and keeping emergency numbers accessible.

4. Workflow Integration & Preference-Informed Decision-Making

Clear Reporting Pathways: Establish explicit symptom escalation thresholds on printed patient cards:

Immediate ("Call Now / Red Flags"): New or severe confusion, behavioral changes, seizures, loss of consciousness, jaundice, or fever with abdominal pain.
Graded ("Call Soon"): Progressive neuropathy impacting daily activities, persistent nausea/vomiting, or new palpitations/syncope.
Multidisciplinary Workflow Alignment:
Utilize scripted nurse triage to conduct standardized symptom assessments upon patient contact.
Schedule proactive clinical touchpoints (e.g., nurse phone check-ins at Day 3 and Week 2).
Integrate multidisciplinary specialty teams early—including oncology, pharmacy (for drug-drug interaction screening), social work (for transportation, language, and financial barriers), neurology, and hepatology.
Dynamic Preference Re-Evaluation:
Revisit the benefit-risk balance continuously across treatment decision nodes (e.g., disease progression, new toxicity, major life events).
Ask direct, preference-eliciting questions (e.g., "What matters most to you right now: staying mentally sharp, avoiding hospital stays, or maximizing treatment response?").
Adapt therapy (dosing holds, reductions, or switching agents) based on evolving patient values and document shared decision-making rationales clearly within the clinical record.

Content is accurate as of the date of release.